Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Aug 2024 Status changed from active, no longer recruiting to completed.
17 Apr 2024 According to Enanta Pharmaceuticals media release, data from the study has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27-30 in Barcelona, Spain.
08 May 2023 According to Enanta Pharmaceuticals media release, full data from SPRINT will be presented at a future medical meeting or in a peer-reviewed publication.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com